Skip NavigationSkip to Content
Return Return to Search Results

Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer

  1. Author:
    Sissung, T. M.
    Thordardottir, S.
    Gardner, E. R.
    Figg, W. D.

  2. Author Address

    Figg, William D.] NCI, Clin Pharmacol Program, Med Oncol Clin Res Unit, Med Oncol Branch,Ctr Canc Res, Bethesda, MD 20892 USA. [Thordardottir, Silja] Univ Iceland, Fac Pharmaceut Sci, Reykjavik, Iceland. [Gardner, Erin R.] SAIC Frederick Inc, Clin Pharmacol Program, NCI Frederick, Frederick, MD 21702 USA.
    1. Year: 2009
  2. Journal: Anti-cancer agents in medicinal chemistry
    1. 9
    2. 10
    3. Pages: 1058-1069
  4. Type of Article: Article
  1. Abstract:

    Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel